Clinical Research & Trials

Physician-Scientists Advance Cardiovascular Care Through Leading-Edge Clinical Research and Innovation

University Hospitals Harrington Heart & Vascular Institute’s Research & Innovation Center was established in 2006 in affiliation with the Case Cardiovascular Research Institute to foster discoveries in cardiovascular disease, therapies and technologies. Our team currently manages 85 trials and follows more than 2,500 patients. The trials represent first-in-human and Phase I to IV studies in interventional cardiology, electrophysiology, peripheral vascular disease, heart failure, cardiac surgery and anesthesiology, cardiovascular imaging and general cardiovascular medicine.

Program Features

Building upon a legacy of innovation that began nearly 150 years ago at University Hospitals Cleveland Medical Center, a number of programs and initiatives are helping forge medicine’s future, translating cardiovascular advances at the earliest stages of their development into improved patient care.

  • 70 faculty, fellows and staff conducting cardiovascular research with committed federally funded research exceeding $30 million
  • One of the most comprehensive cardiovascular imaging programs in the nation with state-of-the-art nuclear medicine, MRI, CT, vascular, cardiac catheterization and electrophysiology laboratories, including the novel Stereotaxis, NOGA and robotic 3-D navigation systems
  • World’s premier program in optical coherence tomography (OCT), a novel vascular imaging technology that provides micron-scale images of the coronary arteries
  • One of the largest calcium score preventive and therapeutic programs in the nation
  • A nationally recognized adult, nonembryonic, stem cell research center and leader of the Ohio Cell-Based Therapy Consortium
  • One of 45 sites nationally exploring expanded indications for transcatheter aortic valve replacement (TAVR, i.e. low and intermediate risk)
  • The first multidisciplinary Immuno-Cardiovascular Center for Cellular Diagnosis dedicated to discovery of novel immunological and cellular mechanisms of heart and vascular diseases
  • Leading worldwide clinical investigations of CardioKinetix’s first-of-its-kind catheter-based Parachute™ Ventricular Partitioning Device, a percutaneous ventricular restoration (PVR) therapy technology for patients with ischemic heart failure
  • International programs to eradicate rheumatic heart disease in underdeveloped countries
  • International network of leading academic medical centers in Europe, Asia, Japan, Africa and South America dedicated to expanding the frontiers of new technologies and therapies

These and other UH Cleveland Medical Center advances are poised to benefit the lives of patients affected by heart and vascular diseases for generations to come.

Clinical Research Studies

A sample of the clinical research studies in progress within our center include:

  • Transcatheter Aortic Valve Replacement (TAVR): For patients with aortic stenosis who are at high or extreme risk for surgical aortic valve replacement, transcatheter aortic valve replacement (TAVR) is an effective option. UH Harrington Heart & Vascular Institute cardiologists are among the first in the country to use a fully percutaneous, conscious sedation approach for TAVR. What was previously major open-heart surgery is now being performed on an awake and talking patient with excellent results. The Interventional Cardiovascular Center of UH Harrington Heart & Vascular Institute is recognized as a high-volume Center of Excellence and is now a training center for the minimalist, percutaneous conscious sedation TAVR approach.
  • Left Ventricular Parachute: Following anterior myocardial infarction (MI), some patients develop adverse left ventricular remodeling that results in left ventricular (LV) dilation, antero-apical aneurysm formation and heart failure. Patients with severe heart failure (Class III – IV) refractory to optimal medical therapy, including cardiac resynchronization therapy, may be candidates for the Parachute™ Ventricular Partitioning Device by CardioKinetix. The device partitions the antero-apical aneurysm, restoring optimal LV volume and geometry. UH Harrington Heart & Vascular Institute at UH Cleveland Medical Center is a leading enrolling center for the implantation of this investigational device percutaneously through the femoral artery.
  • Regenerative Medicine Approaches for Heart and Vascular Disease: Researchers are investigating the use of adult stem cell transplant for patients with severe coronary artery disease (CAD), heart failure with reduced ejection fraction (HFrEF) or advanced peripheral arterial disease (PAD). Two trials, Revive CLI and MarrowStimTM PAD Kit IDE, involve the use of autologous adult stem cells to help the body enhance blood flow in the legs. Results from these trials may provide a promising alternative for patients who are facing amputation and have no other options. UH Harrington Heart & Vascular Institute is also participating in an adult stem cell trial for heart failure using adipose-derived stems obtained from a liposuction procedure to enhance myocardial performance.
Back to Top